Endoxifen is under clinical development by Jina Pharmaceuticals and currently in Phase III for Bipolar I Disorder. According to GlobalData, Phase III drugs for Bipolar I Disorder have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Endoxifen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Endoxifen overview
Endoxifen is under development for treatment of bipolar 1 disorder. The drug candidate is formulated as enteric coated tablet for oral administration and is also administered through topical route. Endoxifen is an active metabolite of tamoxifen. It has anti-estrogen and antineoplastic activity. Endoxifen is based on the Nanoaqualip Technology. The drug candidate was also under development for metastatic breast cancer.
Jina Pharmaceuticals overview
Jina Pharmaceuticals (Jina Pharma) is a biopharmaceutical company that focuses on research, development and commercialization of novel therapeutic products. The company designs novel lipid molecules, lipid-drug conjugates, and new functional lipid molecules that can have better therapeutic effects against various diseases. It also conducts research in developing lipids that can effective deliver nucleic acids such as antisense oligonucleotides, siRNA and miRNA. These lipid molecules can facilitate in the delivery of hydrophobic drugs and also enable the delivery of functional RNA and DNA molecules in vivo. Its therapeutic areas include cancer, infectious diseases, and acute medical emergencies. Jina Pharma is headquartered in Libertyville, Illinois, the US.
For a complete picture of Endoxifen’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
